Monthly
US$200
Billed every month
Bromfenac Sodium Eye Drops(溴芬酸钠滴眼液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 3 applicationsNo longer listed under review: 1 applicationSupplement delivery: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders1View records ↓
Under-review filings7View records ↓
This year’s generic filers4View records ↓
NHSA approval numbers29View records ↓
API companies with A status14View records ↓
Chemical-drug catalogue
Loaded records: 1 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| SENJU PHARMACEUTICAL CO., LTD. | SENJU PHARMACEUTICAL CO., LTD. Karatsu Plant | H20150243 | 2009/09/29 | 0.1%（5ml:5mg，按C15H11BrNNaO3·1½H2O计） | Imported originator drug (进口原研药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 29 distinct approval numbers and 22 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 广东众生药业股份有限公司 | 国药准字H20233262 | 0.1%(5ml∶5mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010010100371 | NHSA |
| 津药和平(天津)制药有限公司 | 国药准字H20213053 | 0.1%(5ml:5mg,按C15H11BrNNaO3·11/2H2O计) | Category B (乙) | XS01BCX230G010010100952 | NHSA |
| 沈阳兴齐眼药股份有限公司 | 国药准字H20244468 | 0.1%(5ml:5mg,按C15H11BrNNaO3·1½H2O 计) | Category B (乙) | XS01BCX230G010010101322 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20234193 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010010101503 | NHSA |
| 武汉五景药业有限公司 | 国药准字H20244284 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃•1½H₂O计) | Category B (乙) | XS01BCX230G010010101978 | NHSA |
| 成都普什制药有限公司 | 国药准字H20256506 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·1 ₁/₂H₂O | Category B (乙) | XS01BCX230G010010102298 | NHSA |
| 齐鲁制药有限公司 | 国药准字H20183490 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·3/2H₂O计) | Category B (乙) | XS01BCX230G010010104021 | NHSA |
| 济南辰欣医药科技有限公司 | 国药准字H20150022 | 5ml:5mg(0.1%) | Category B (乙) | XS01BCX230G010010104127 | NHSA |
| 合肥华威药业有限公司 | 国药准字H20244569 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010010104388 | NHSA |
| 浙江莎普爱思药业股份有限公司 | 国药准字H20253221 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010010104693 | NHSA |
| 江西马应龙美康药业有限公司 | 国药准字H20264422 | 0.1%(5ml:5mg,按 C₁₅H₁₁BrNNaO₃•1½H₂O计) | Category B (乙) | XS01BCX230G010010105293 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20233640 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃•11/2H₂O计) | Category B (乙) | XS01BCX230G010010105847 | NHSA |
| 辽宁美滋林药业有限公司 | 国药准字H20193244 | 0.1%(5ml:5mg,按C15H11BrNNaO33/2H2O计) | Category B (乙) | XS01BCX230G010010106441 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20243868 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃•1½H₂O计) | Category B (乙) | XS01BCX230G010010109920 | NHSA |
| 河北创健药业有限公司 | 国药准字H20243677 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010010110364 | NHSA |
| SENJU PHARMACEUTICAL CO.,LTD. | 国药准字HJ20150243 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃·11/2H₂O计) | Category B (乙) | XS01BCX230G010010179077 | NHSA |
| 武汉先路医药科技股份有限公司 | 国药准字H20213554 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃ ▪1 1/2 H₂O | Category B (乙) | XS01BCX230G010010181567 | NHSA |
| 苏州欧康维视生物科技有限公司 | 国药准字H20253042 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010010183562 | NHSA |
| 广州仁恒医药科技股份有限公司 | 国药准字H20255727 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010010184019 | NHSA |
| 武汉先路医药科技股份有限公司 | 国药准字H20247205 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃ •11/2 | Category B (乙) | XS01BCX230G010010184190 | NHSA |
| 成都普什制药有限公司 | 国药准字H20256506 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·1 ₁/₂H₂O | Category B (乙) | XS01BCX230G010010202298 | NHSA |
| 齐鲁制药有限公司 | 国药准字H20183490 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·3/2H₂O计) | Category B (乙) | XS01BCX230G010010204021 | NHSA |
| 济南辰欣医药科技有限公司 | 国药准字H20150022 | 5ml:5mg(0.1%) | Category B (乙) | XS01BCX230G010010204127 | NHSA |
| 广州仁恒医药科技股份有限公司 | 国药准字H20255727 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010010284019 | NHSA |
| 武汉先路医药科技股份有限公司 | 国药准字H20247205 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃ •11/2 | Category B (乙) | XS01BCX230G010010284190 | NHSA |
| 润尔眼科药物(广州)有限公司 | 国药准字H20244161 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃•1½H₂O计) | Category B (乙) | XS01BCX230G010010284784 | NHSA |
| 成都普什制药有限公司 | 国药准字H20256506 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·1 ₁/₂H₂O | Category B (乙) | XS01BCX230G010010302298 | NHSA |
| 济南辰欣医药科技有限公司 | 国药准字H20150022 | 5ml:5mg(0.1%) | Category B (乙) | XS01BCX230G010010304127 | NHSA |
| 广州仁恒医药科技股份有限公司 | 国药准字H20255727 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010010384019 | NHSA |
| 武汉先路医药科技股份有限公司 | 国药准字H20247205 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃ •11/2 | Category B (乙) | XS01BCX230G010010384190 | NHSA |
| 成都普什制药有限公司 | 国药准字H20256506 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·1 ₁/₂H₂O | Category B (乙) | XS01BCX230G010010402298 | NHSA |
| 济南辰欣医药科技有限公司 | 国药准字H20150022 | 5ml:5mg(0.1%) | Category B (乙) | XS01BCX230G010010404127 | NHSA |
| 广州仁恒医药科技股份有限公司 | 国药准字H20255727 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010010484019 | NHSA |
| 武汉先路医药科技股份有限公司 | 国药准字H20247205 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃ •11/2 | Category B (乙) | XS01BCX230G010010484190 | NHSA |
| 广州仁恒医药科技股份有限公司 | 国药准字H20255727 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010010584019 | NHSA |
| 武汉先路医药科技股份有限公司 | 国药准字H20247205 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃ •11/2 | Category B (乙) | XS01BCX230G010010584190 | NHSA |
| 津药和平(天津)制药有限公司 | 国药准字H20223699 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010020100952 | NHSA |
| 齐鲁制药有限公司 | 国药准字H20183491 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃·3/2H₂O计) | Category B (乙) | XS01BCX230G010020104021 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20233366 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃•1½H₂O计) | Category B (乙) | XS01BCX230G010020104127 | NHSA |
| 浙江莎普爱思药业股份有限公司 | 国药准字H20253220 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010020104693 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20243922 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃•1½H₂ O计) | Category B (乙) | XS01BCX230G010020109920 | NHSA |
| 苏州欧康维视生物科技有限公司 | 国药准字H20263589 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·1½H₂O计) | Category B (乙) | XS01BCX230G010020183562 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20233366 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃•1½H₂O计) | Category B (乙) | XS01BCX230G010020204127 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20233366 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃•1½H₂O计) | Category B (乙) | XS01BCX230G010020304127 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20233366 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃•1½H₂O计) | Category B (乙) | XS01BCX230G010020404127 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20243868 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃•1½H₂O计) | Category B (乙) | XS01BCX230G010030109920 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20243868 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃•1½H₂O计) | Category B (乙) | XS01BCX230G010030209920 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20243868 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃•1½H₂O计) | Category B (乙) | XS01BCX230G010030309920 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20243868 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃•1½H₂O计) | Category B (乙) | XS01BCX230G010030409920 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20243868 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃•1½H₂O计) | Category B (乙) | XS01BCX230G010030509920 | NHSA |
| 艾视制药有限公司 | 国药准字H20264661 | 0.1%(0.4ml:0.4mg,按C₁₅H₁₁BrNNaO₃·1½H₂O 计) | Category B (乙) | XS01BCX230G010010185580 | NHSA |
| 艾视制药有限公司 | 国药准字H20264662 | 0.1%(5ml:5mg,按C₁₅H₁₁BrNNaO₃·1½H₂O 计) | Category B (乙) | XS01BCX230G010020185580 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 7 filings and 6 distinct first applicants.
Generic 7
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏远恒药业有限公司 | CYHS2602322 | Generic | 2026/09/17 | Not stated by source | CDE |
| 山东海山药业有限公司;山东威智百科药业有限公司 | CYHS2602111 | Generic | 2026/08/25 | Not stated by source | CDE |
| 石家庄四药有限公司 | CYHS2601517 | Generic | 2026/06/26 | Not stated by source | CDE |
| 广东南国药业有限公司 | CYHS2601081 | Generic | 2026/05/12 | Not stated by source | CDE |
| 石家庄格瑞药业有限公司 | CYHS2504444 | Generic | 2025/12/27 | Not stated by source | CDE |
| 石家庄格瑞药业有限公司 | CYHS2504443 | Generic | 2025/12/27 | Not stated by source | CDE |
| 湖北美林药业有限公司 | CYHS2503161 | Generic | 2025/08/29 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 4 filings and 4 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏远恒药业有限公司 | CYHS2602322 | Generic | 2026/09/17 | Not stated by source | CDE |
| 山东海山药业有限公司;山东威智百科药业有限公司 | CYHS2602111 | Generic | 2026/08/25 | Not stated by source | CDE |
| 石家庄四药有限公司 | CYHS2601517 | Generic | 2026/06/26 | Not stated by source | CDE |
| 广东南国药业有限公司 | CYHS2601081 | Generic | 2026/05/12 | Not stated by source | CDE |
API registrations
Non-component matches: 14 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 溴芬酸钠 | 石家庄格瑞药业有限公司 | Y20250000320 | A | Exact ingredient | 2026/10/12 | CDE |
| 溴芬酸钠 | 浙江赛默制药有限公司 | Y20240000502 | A | Exact ingredient | 2025/12/17 | CDE |
| 溴芬酸钠 | Medilux Laboratories Pvt. Ltd | Y20230000372 | A | Exact ingredient | 2026/07/12 | CDE |
| 溴芬酸钠 | 中山万汉制药有限公司 | Y20220000433 | A | Exact ingredient | 2024/03/11 | CDE |
| 溴芬酸钠 | 河北安健成益医药科技有限公司 | Y20210000778 | A | Exact ingredient | 2024/04/09 | CDE |
| 溴芬酸钠 | 广州华圣制药有限公司 | Y20210000006 | A | Exact ingredient | 2025/04/16 | CDE |
| 溴芬酸钠 | 广东先强药业有限公司 | Y20200001049 | A | Exact ingredient | 2025/03/27 | CDE |
| 溴芬酸钠 | YS Life Science Co., Ltd. | Y20190021249 | A | Exact ingredient | 2024/07/27 | CDE |
| 溴芬酸钠 | 武汉先路医药科技股份有限公司 | Y20190000875 | A | Exact ingredient | 2026/06/02 | CDE |
| 溴芬酸钠 | 山东辰龙药业有限公司 | Y20190001971 | A | Exact ingredient | 2024/09/27 | CDE |
| 溴芬酸钠 | 津药药业股份有限公司 | Y20170002121 | A | Exact ingredient | 2025/06/12 | CDE |
| 溴芬酸钠 | Indoco Remedies Ltd. (Kilo Lab) | Y20170001316 | A | Exact ingredient | 2026/05/06 | CDE |
| 溴芬酸钠 | 齐鲁制药有限公司 | Y20170000569 | A | Exact ingredient | 2024/09/04 | CDE |
| 溴芬酸钠 | 辽宁天龙药业有限公司 | Y20170000249 | A | Exact ingredient | 2024/09/12 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/29No longer listed under review
山东海山药业有限公司
CYHS2502163
Fact date: 2026/10/29 · Site observation date: 2026/10/29
Accepted: 2025/06/17
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/10/16Supplement delivery
山东辰欣佛都药业股份有限公司
CYHB2601321 · 国药准字H20269252
Fact date: 2026/10/16 · Publication date: 2026/10/19 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 7 ↗ -
2026/09/17Accepted
-
2026/08/25Accepted
山东海山药业有限公司;山东威智百科药业有限公司
CYHS2602111
Fact date: 2026/08/25 · Site observation date: 2026/10/22
View source ↗ -
2026/08/24Accepted
SENJU PHARMACEUTICAL CO. LTD.;SENJU PHARMACEUTICAL CO. LTD. Karatsu Plant
JYHB2600490
Fact date: 2026/08/24 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Bromfenac Sodium Eye Drops
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy